SCHEMBL3741530

SCHEMBL3741530

Fc1ccc2c(c1)C1(CCNCC1)OC2C1CCCCC1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 1/20 0.35
▸ HTR2C P28335 4/20 0.34
▸ SLC6A2 P23975 3/20 0.34
▸ KDM1A O60341 2/20 0.34
▸ HTR1A P08908 2/20 0.34
▸ SLC6A4 P31645 2/20 0.34
▸ SLC6A3 Q01959 2/20 0.34
▸ HTR2A P28223 2/20 0.34
▸ HTR6 P50406 1/20 0.33
▸ OPRM1 P35372 1/20 0.31
▸ OPRK1 P41145 1/20 0.31
▸ OPRL1 P41146 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ DPP4 P27487 1/20 0.31
▸ CHRNB2 P17787 1/20 0.31
▸ CHRNB4 P30926 1/20 0.31
▸ CHRNA3 P32297 1/20 0.31
▸ CHRNA4 P43681 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3751282 0.77 HTR2C (0.40) SIGMAR1HTR2CKDM1AHTR2AHTR6
SCHEMBL3750826 0.75 HTR2C (0.35) SIGMAR1HTR2CKDM1AHTR2ADPP4
SCHEMBL3750526 0.71 DGAT1 (0.36) SIGMAR1HTR2CSLC6A2SLC6A4SLC6A3
SCHEMBL11397134 0.66 TMEM97 (0.42) SIGMAR1OPRM1
SCHEMBL1587932 0.64 DPP4 (0.43) HTR2CKDM1AOPRL1KMT2ADPP4
SCHEMBL22057308 0.64 NPY5R (0.45) SIGMAR1HTR2CDPP4
SCHEMBL27767462 0.64 DPP4 (0.36) SIGMAR1HTR2COPRM1OPRK1OPRL1
SCHEMBL11686154 0.64 PRCP (0.43) SIGMAR1SLC6A2HTR1ASLC6A4SLC6A3
SCHEMBL750605 0.63 HTR2C (0.39) SIGMAR1HTR2CKDM1AHTR2AKMT2A
Hydrochloric Acid SCHEMBL3561180 0.63 DPP4 (0.42) HTR2CKDM1AOPRL1KMT2ADPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7834008-B2 neurokinin receptor 3 (NK3) antagonists; psychological disorders, inflammatory bowel disease, asthma, ischemia, Parkinson's disease; e.g. (1S,2R)-2-(4-Acetylamino-4-phenyl-piperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)-cyclopropanecarboxylic acid, benzyl-methyl-amide H. LUNDBECK A/S (DK) 2010-11-16 — — US disclosed
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 — — US disclosed
US-20060281746-A1 Cyclopropyl derivatives as nk3 receptor antagonists H. LUNDBECK A/S (DK) 2006-12-14 — — US disclosed
EP-1656349-A1 CYCLOPROPYL DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS H. Lundbeck A/S (DK) 2006-05-17 — — EP disclosed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 — — US disclosed
WO-2005016884-A1 CYCLOPROPYL DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS H. LUNDBECK A/S (DK) 2005-02-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives KCNJ2, KCNK2, KCNJ11 SIGMAR1 1345/4885HTR2C 504/4885SLC6A2 112/4885
US-20060281746-A1 Cyclopropyl derivatives as nk3 receptor antagonists TACR2, SLC6A3, TACR1 SIGMAR1 680/4885HTR2C 708/4885SLC6A2 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback